Author(s):
Fatma Abdalhamza Obed, Noorhan Khalid Shafeeq, Raghda Shams Akram, Elaf Zuhair Hmeed
Email(s):
aliomran662000@yahoo.com , noorhan.albayaty@gmail.com
DOI:
10.52711/0974-360X.2023.00022 
Address:
Fatma Abdalhamza Obed1, Noorhan Khalid Shafeeq2, Raghda Shams Akram3, Elaf Zuhair Hmeed4
1Hematological Center, AL-Mustansiriya University, Baghdad, Iraq.
2Department of Chemistry/ College of Education, For Pure Science (Ibn-Al-Haitham) University of Baghdad. Iraq.
3Department of chemistry and Biochemistry, College of medicine, Mustansiriyah University, Baghdad, Iraq.
4Hematological Center, AL-Mustansiriya University, Baghdad, Iraq.
*Corresponding Author
Published In:
Volume - 16,
Issue - 1,
Year - 2023
ABSTRACT:
Acute myeloid leukemia (AML) is a clonal disease that manifests itself in the bone marrow as a hyper proliferative immature myeloid cells with a defective differentiation program. In adults, Acute leukemia is the most frequent type of cancer. The most common causes of death among patients include severe infections, resistance, and relapses. Recent research has suggested that the disease is caused by a collection of hematopoietic stem cell mutations accumulated over time. the study was carried out to detect how high sensitive C-reactive protein (hs-CRP) affected newly diagnosed Acute Myeloid Leukemia patients with other co morbidity and diabetes insipidus.in Conclusion; Increased high sensitive (c-reactive protein) (hs-CRP) could be act as predictive factor in individuals with diabetes and other hematological changes who have acute myeloid leukemia. Aim of study: the study was carried out to detect how high sensitive C-reactive protein (hs-CRP) affected newly diagnosed Acute Myeloid Leukemia patients with other co morbidity and diabetes insipidus. Conclusion: Increased high sensitive (c-reactive protein) (hs-CRP) could be act as predictive factor in individuals with diabetes and other problem who have acute myeloid leukemia. Furthermore the causes between association with diabetes insipidus are not understood.
Cite this article:
Fatma Abdalhamza Obed, Noorhan Khalid Shafeeq, Raghda Shams Akram, Elaf Zuhair Hmeed. Study the Effect of High Sensitive-C reactive protein in newly Diagnosed Acute Myeloid Leukemia with other Hematological markers. Research Journal of Pharmacy and Technology 2023; 16(1):119-122. doi: 10.52711/0974-360X.2023.00022
Cite(Electronic):
Fatma Abdalhamza Obed, Noorhan Khalid Shafeeq, Raghda Shams Akram, Elaf Zuhair Hmeed. Study the Effect of High Sensitive-C reactive protein in newly Diagnosed Acute Myeloid Leukemia with other Hematological markers. Research Journal of Pharmacy and Technology 2023; 16(1):119-122. doi: 10.52711/0974-360X.2023.00022 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-1-22
REFRENCES:
1. Döhner H, Weisdorf DJ, Bloomfi eld CD. Acute myeloid leukemia. N Engl J Med 2015sep 17(12);373:1136-52; doi: 10.1056/NEJMra 1406184.
2. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratifi cation and management. Am J Hematol 2013;88:318-27. doi: 10.1002/ajh.23404
3. Chang F, Shamsi TS, Waryah AM. Clinical and hematological profi le of acute myeloid leukemia (AML) patients of Sindh. J Hematol Thromb Dis 2016;4(2):1-5. doi:10.4172/ 23298790.1000239
4. Ding, L.; Ley, T.J.; Larson, D.E.; Miller, C.A.; Koboldt, D.C.; Welch, J.S.; Ritchey, J.K.; Young, M.A.; Lamprecht, T.; McLellan, M.D. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012,jul26; 481(7382), 506–510. doi: 10.1038/nature10738.
5. P Smits, T de Witte, C Haanen, J, Diabetes insipidus occurring with acute leukaemia, Neth j Med 1989 Jun;34(5-6):264-9.case report.
6. Puolakka K., Korhonen T., Lahtinen R. Diabetes insipidus in preleukaemic phase of acute myeloid leukaemia in 2 patients with empty sella turcica. A report of 2 cases, Scand. J. Haematol. 32 (1984) 364–366 . doi.org/10.1016/0145-2126(92)90022-Y
7. Ali KA, Alwan FA, Mohammed MH . C- Reactive protein and iron status in Iraqi patients with acute myeloid leukemia before and after treatment. International J of Pharma and Chemical Research .2016 jul.2(3):149-157.
8. Najjar SA, Al Tameemi WF Application of serum C‑reactive protein in comparison with βeta‑2‑microglobulin in patient with multiple myeloma Iraqi J Hematol 2017;6(1):6-11; DOI: 10.4103/ijh.ijh_3_17
9. Isidori A, Salvestrini V, Ciciarello M, Loscocco F, Visani G, and Parisi S. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev Hematol; 2014 Dec;7(6):807-18. doi: 10.1586/ 17474086. 2014. 958464
10. Wang ES. Treating acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program 2014Dec 5;2014(1):14-20. doi: 10.1182/asheducation-2014.1.14. Epub 2014 Nov 18.
11. Jennifer N,S and Ramior G. Acute myeloid leukemia: Aconcess Review;J.Clin.Med.2016,March5;5(3);33:2-17,doi;10.3390/jmc 5030033
12. Ahmed HS, Tahir TN, Obed FA. Cytokines profiling as prognostic markers in newly diagnosed acute myeloid leukemia. Iraqi Journal of Hematology. 2017:6(2) .p65-68. DOI: 10.4103/ijh.ijh_20_17
13. Chang F, Shamsi TS, Waryah AM. Clinical and hematological profi le of acute myeloid leukemia (AML) patients of Sindh. JHematol Thromb Dis 2016;4(2):1-5. DOI: 10.4172/2329-8790 1000239
14. Cengiz D, Halit D, Ramazan E, Abidin S, and Murat A. Altraion serum level of elements in Acute Leukemia Cases in Turkey. Asian Pacific Journal of cancer Prevention .2011, 12(:3471-3473.
15. Chang F, Shamsi TS, Waryah AM. Clinical and hematologicalprofi le of acute myeloid leukemia (AML) patients of Sindh. J Hematol Thromb Dis 2016;4:1-5.
16. Sato M , et al. Predication of infections events by high sensitive c reactive protein level befor undergoing chemotherapy for acute myeloid leukemia . Scand J Infect Dis . 2010,42(2).97-101.doi.org/10/3109/ 00365540903331019
17. Ann Y.Liu , FrankC.Curriero , Thomas A.Glass c, Walter F. Stewart, BrianS. Schwartz . The contextual influence of coal abandoned mine landsin communities and type2 diabetes in Pennsylvania. Health&Place .2013. 22 : 115–122.
18. Usman H , Rashed R, Ameer F, Iqbal A, Zaid M, Hasanin S, and Zaid N. Revisiting The dyslipedemia association with acute leukemia.Clin,Chem,Acta.2015.444:-43-49. https://doi.org/10.1016 /j.cca.2015.01.038
19. Delavigne, K. Bearad E, Bertoil S, Corre J , Duchayne E, Demur C, MancetM, Sarry A, Huguet F, and Recher C. Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy. Haematologica 2014March, 99(3), pp.474–480; doi: 10.3324/haematol.2013.097394. Epub 2013 Oct 18.
20. Areeb I, et al. Atypical plasma lipid profile in leukemia. Clin Chim
21. Acta .2016Jan.452:129-133. doi: 10.1016/j.cca.2015.11.003.
22. Einollahi N , Alizadeh Sh, Dashti N, Nabatchian F, Zare Bovani M, Abbasi S , Mohamadian M, Kashani Khatib Z. Serum Lipid Profile Alterations in Acute Leukemia Before and After Chemotherapy. IJBC 2013;6(1): 3-9; DOI: 10.5897/IJBC
23. Morel S, et al . Lipid and Lipoprotein abnormalities in acute lymphoblastic leukemia survivors. J . Lipid Res. 2017 May;58(5):982-993. doi: 10.1194/jlr.M072207. Epub 2017 Mar 8.
24. Rosemary H, and Gerald M. Acute myeloid leukemia with diabetes insipidus and hypophyseal infiltration. Asia-Pacifi c Journal of Clinical Oncology 2016;12(2):p97-139 e350–e351, https://doi.org/10.1111/ajco.12257